Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bispecific ANGPTL3-DGAT2 siRNA
- Development stage
- Preclinical
- Lead developer
- ARGONAUTE RNA
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
bispecific ANGPTL3-DGAT2 siRNA is a preclinical-stage bispecific small interfering RNA (siRNA) therapeutic developed by Argonaute RNA Ltd in collaboration with the University of Cambridge. Utilizing Argonaute's proprietary PULSE siRNA™ platform, the drug is designed for the simultaneous silencing of both angiopoietin-like protein 3 (ANGPTL3) and diacylglycerol O-acyltransferase 2 (DGAT2) in hepatocytes. This dual-targeting approach aims to concurrently treat hepatic steatosis and reduce the residual risk of atherosclerotic cardiovascular disease (ASCVD) by lowering both liver fat accumulation and atherogenic plasma lipids (such as LDL-C and triglycerides) without inducing the adverse lipid profiles associated with single-target therapies.
- Other names
- ANGPTL3/DGAT2 bispecific siRNAANGPTL3/DGAT2 siRNAbispecific Angptl3-Dgat2 siRNA
02
Targets
ANGPTL3 (Angiopoietin-like protein 3)DGAT2 (Hepatic diacylglycerol acyltransferase 2)
Beyond the preview
Go deeper on bispecific ANGPTL3-DGAT2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bispecific ANGPTL3-DGAT2 siRNA.